CHU Amiens-Picardie
Amiens, 80054, France
NCT Number: NCT03687099
Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis. Immunotherapy by checkpoint inhibitors (PD1 /PDL-1) appears as a promising treatment for many cancers. However, first clinical results are disappointing for GBM. An hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. Conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Amiens, 80054, France
An important and constant infiltration of cells marked with CD45 has been observed in 77 GBM studied for the prognostic value of PDL1 and IL17 infiltration (in association with Pr Ghiringhelli ; INSERM ; Dijon) . However, CD45 is present at the surface of all leucocytes. The purpose of this project is to better characterize the nature and functionality of the CD45+ cells that infiltrate GBM (lymphocytes and their sub-types, macrophages, microglial cells). Formalin-fixed paraffin-embedded GBM samples will be studied. A panel of immune cell antibody will be used for the immuno-histological (IH) study. Furthermore, the investigator will compare these data with those obtained by the nanoString technology, a multiplexed measurement of gene expression.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
Time frame: 1
number of cells which express CD45 in the immunological environment from GBM, with using NanoString/RNAseq (NGS) and immunohistology
Centre Hospitalier Universitaire, Amiens
Other
Acronym: GLIOBLASTOMES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01339052
Astrocytoma, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT02902757
Astrocytoma, Glioblastoma
Los Angeles, California, United States
View Trial DetailsNCT05635734
Astrocytoma, Glioblastoma
Barcelona, Spain
View Trial DetailsNCT03477513
Astrocytoma, Glioblastoma
Philadelphia, Pennsylvania, United States
View Trial Details